Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.87 USD | +6.04% | +4.25% | +33.03% |
Business Summary
Number of employees: 186
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule Therapeutics
100.0
%
| 47 | 100.0 % | 79 | 100.0 % | +67.84% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 47 | 100.0 % | 79 | 100.0 % | +67.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 15-08-31 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 19-07-14 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-04 |
Kevin Dushney
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-02 |
Jared Gollob
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-08-31 |
Vijay Sabesan
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-12-05 |
Jeremy Chadwick
COO | Chief Operating Officer | 61 | 23-05-21 |
Investor Relations Contact | - | 23-06-30 | |
Aimee Mishkin
LAW | General Counsel | - | 20-03-31 |
Melissa Brody
PRN | Corporate Officer/Principal | - | 21-11-01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | Mar. 27 |
Joanna Horobin
BRD | Director/Board Member | 69 | 18-04-30 |
John Maraganore
BRD | Director/Board Member | 60 | 22-01-16 |
Elena Ridloff
BRD | Director/Board Member | 44 | 21-03-11 |
Bruce Booth
FOU | Founder | 49 | 15-08-31 |
Pamela Esposito
BRD | Director/Board Member | 50 | 20-09-03 |
Jeffrey Albers
BRD | Director/Board Member | 52 | 20-06-30 |
Leigh Morgan
BRD | Director/Board Member | 56 | 22-07-07 |
Victor Sandor
BRD | Director/Board Member | 57 | 22-11-02 |
Nello Mainolfi
FOU | Founder | 45 | 15-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 61,358,262 | 60,591,112 ( 98.75 %) | 0 | 98.75 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.03% | 1.96B | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- KYMR Stock
- Company Kymera Therapeutics, Inc.